How evidence-based medicine biases physicians against nutrition

Laurie Endicott Thomas, MA, ELS

28 Niles Ave., Madison, NJ 07940, United States

A R T I C L E   I N F O
Article history:
Received 9 July 2013
Accepted 11 October 2013

A B S T R A C T

Medical students in the United States are taught little about nutrition and dietetics. Worse yet, their training biases them against the studies that show the power of dietary approaches to managing disease. The current approach to evidence-based medicine encourages physicians to ignore any information that does not come from a double-blind, randomized controlled trial. Yet human beings cannot be blinded to a dietary intervention. As a result, physicians are biased toward drug treatments and against dietary interventions for the management of chronic disease.

While British surgeon Denis Parsons Burkitt was working in Africa, he noticed that many of the noninfectious chronic diseases that were common in Britain were rare among Africans who were following a traditional lifestyle. Examples included coronary artery disease, diabetes, colon cancer, appendicitis, and even varicose veins. Burkitt suggested that these “Western” diseases were largely due to a high-fat, low-fiber diet. He was eventually dubbed “the Fiber Man” for his insistence on the importance of a low-fat, high-fiber diet [1].

Western diseases are major causes of death and disability in the United States (Fig. 1) [2]. Even arthritis, the number 1 cause of disability in the United States [3], has a dietary component. Some physicians from the United States believe that osteoarthritis is due to “wear and tear” on the joints [4], yet osteoarthritis is relatively uncommon in Africa, where most of the population does most of its work by hand [5].

Burkitt argued that the Western diseases are easy to prevent but hard to cure. As he put it, if people are constantly falling off a cliff, you could place ambulances at the foot of a cliff or build a fence on the top of the cliff. He argued that we are placing too many ambulances at the foot of the cliff. Burkitt emphasized the importance of fiber in the diet and the dangers of fat: “The frying pan you should give to your enemy. Food should not be prepared in fat. Our bodies are adapted to a stone age diet of roots and vegetables” [6].

Unfortunately, medical students in the United States and perhaps some other Western industrialized nations are being trained to work the ambulances, not to build the fences. The inadequacy of the nutrition curriculum in American and British medical schools has been a matter of concern since the 1960s [7–12]. Worse yet, the training that students receive in medical school tends to bias them against the kinds of studies that show the power of diet to prevent or even cure Western diseases. The situation is actually getting worse because of the rise of evidence-based medicine. Evidence is a good thing, especially in medicine. However, the medical profession is focusing too much on one kind of evidence, to the exclusion of others [13].

Clinical trials

Medical students in the United States are taught that the double-blind, randomized controlled clinical trial (DBRCT, Table 1) is the gold standard for evaluating cause and effect and for assessing the value of treatments. The DBRCT methodology was developed to eliminate selection bias and observer bias, along with controlling for possible confounding variables.

Although the DBRCT methodology has important strengths, it also has important weaknesses (Table 2). Even the Food and Drug Administration, which requires DBRC Ts to support the approval of new drugs, also relies on the results of other kinds of studies for various purposes.

Unquestionably, DBRCT methodology has important uses. Nevertheless, physicians need to understand that such methodology is not always necessary or even appropriate. Some kinds of DBRTs can never be done. Others should never be done. Still others need never be done. Physicians need a clear understanding of when other kinds of evidence are sufficient and compelling. To clarify these points, it is helpful to understand two historical events: the Nuremberg Trials and the debates about whether cigarette smoking causes lung cancer.

Ethics and practical considerations

After World War II, Americans were shocked by the revelations of barbaric medical “experiments” that had been conducted in Nazi
Concentration camps [14]. The verdict in the Doctors’ Trial at Nuremberg included legal principles that were later expanded into the World Medical Association’s Declaration of Helsinki, which was first issued in 1964 and has been updated periodically [15]. Many of these principles have been incorporated into law in many countries.

One of the basic principles expressed in the Declaration of Helsinki is that “the well-being of the individual research subject must take precedence over all other interests” [15]. In other words, medical researchers cannot deliberately expose people to harm, just to see how sick they get. That is why no one has done a DBRCT to prove that HIV causes AIDS in humans. DBRCTs are rarely if ever done to establish the cause of disease in human beings. Fortunately, other kinds of evidence can be used to establish causality.

The DBRCT methodology is simply impractical for studying some other kinds of problems. For example, one cannot run a DBRCT to prove that cigarette smoking causes lung cancer. Not only would it be impossible and unethical to assign some people to smoke cigarettes, the study would have to last for at least 20 years, long enough for the lung tumors to arise. Nevertheless, by the 1950s, epidemiologic studies had provided solid evidence that cigarette smoking was the major cause of lung cancer. In response, the tobacco industry and its defenders fought hard to muddy the waters.

One of the most effective of the tobacco industry’s supporters was Sir Ronald Aylmer Fisher, a British statistician whose mathematical achievements and promotion of statistical methods in scientific research had revolutionized 20th century science [16]. Fisher’s clever rebuttals of the epidemiologic studies of lung cancer all boiled down to basically the same complaint: that no one had done any DBRCTs, and in the absence of DBRCTS, one could not draw any reliable conclusions [12].

**Epidemiologic methods**

Fortunately, another prominent British statistician saw through Fisher’s smokescreen. Sir Austin Bradford Hill had pioneered the use of DBRCTs in medicine, but he was wise enough to recognize their limitations. Hill came up with a set of considerations (Table 3) to guide inquiry about causality when no DBRCTs can or should be done [17].

Although DBRCTs are useful for evaluating the short-term use of a drug therapy, they are simply impractical for evaluating dietary interventions, for the following reasons:

- People do not necessarily eat what they are told to eat, especially not for any length of time.
- Subjects cannot be blinded to what they are eating.
- To study a rare outcome, such as type 1 diabetes, the study would have to enroll an enormous number of people.
- To study a disease that takes years to develop, the trial would have to last for years.

If people are asked to follow a particular diet for the purposes of an experiment, some of them will, and some of them will not. In the end, the people who stick to their assigned diet will be, to some extent, the experimental subjects who are human beings, as opposed to laboratory animals or cell cultures.

---

**Table 1**

<table>
<thead>
<tr>
<th>Term</th>
<th>What it means</th>
</tr>
</thead>
<tbody>
<tr>
<td>Double-blind trial</td>
<td>Neither the subject nor the person who is evaluating the subject knows what treatment the subject receives</td>
</tr>
<tr>
<td>Randomized trial</td>
<td>Neither the doctor nor the subject chooses what treatment any individual subject gets. Instead, subjects are randomly assigned to one of two or more groups, each of which receives a different kind of treatment</td>
</tr>
<tr>
<td>Placebo</td>
<td>A placebo is a fake treatment that looks like the real thing. A study of a pill might use a lookalike pill as a placebo. A placebo is sometimes called a sugar pill, even though it might not contain sugar. An injection of plain salt water is sometimes used as a placebo in trials of injectable medication. Sham surgery is occasionally used as a control for clinical trials of surgical procedures</td>
</tr>
<tr>
<td>Controlled trial</td>
<td>One group of subjects receives one kind of treatment and another, identical group (controls) receives a different kind of treatment or no treatment at all</td>
</tr>
<tr>
<td>Clinical trial</td>
<td>The experimental subjects are human beings, as opposed to laboratory animals or cell cultures</td>
</tr>
</tbody>
</table>

---

**Table 2**

<table>
<thead>
<tr>
<th>Potential weakness</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size</td>
<td>Clinical trials are designed to be large enough to show differences in how well the drug works, but they are too small to tell us much about rare side effects. That is why regulators rely so much on adverse event reporting for drugs that are already on the market</td>
</tr>
<tr>
<td>Duration</td>
<td>Clinical trials typically involve only a short period of treatment. Thus, they tell us nothing about the risks and benefits of long-term use</td>
</tr>
<tr>
<td>Patient population</td>
<td>Many clinical trials have systematically excluded people who were elderly or sick or were taking other medications. This may make the drug look safer than it really is</td>
</tr>
<tr>
<td>Relevance of the endpoints</td>
<td>To get useful results within a reasonable amount of time and with a reasonable number of subjects, the clinical trial may use some sort of alternative endpoint. For example, a clinical trial may measure how the drug affects the patient’s cholesterol levels, when the real question is whether it saves lives</td>
</tr>
<tr>
<td>Relevance of the comparison</td>
<td>Many clinical trials compare a drug to an inactive treatment (placebo). They do not necessarily compare the drug to the best available alternative, whether it is a different drug or a change in diet</td>
</tr>
<tr>
<td>Context of the study</td>
<td>Given what we already know about this disease, is it even reasonable to do this study? Is this study evaluating treatments for the symptoms of a disease that could easily be cured by other means?</td>
</tr>
</tbody>
</table>
degree, self-selected. So even if a researcher tried to randomize them, they will un-randomize themselves before long. Furthermore, it’s impossible to do a double-blind trial of a diet, because subjects cannot be blinded to what they are eating!

In other words, one simply cannot use the same methodology for studying diet as for studying drugs. Unfortunately, this means that many doctors will ignore all of the studies of diet and focus only on the studies of drugs. As a result, those doctors end up writing prescriptions for drugs instead of teaching their patients how to eat properly—even if the dietary intervention works better than the drugs.

Evidence-based medicine

Medical doctors are focusing even more on drug studies—and paying even less attention to other kinds of studies—because of a trend that is officially called evidence-based medicine. Unfortunately, this approach can easily degenerate into ignoring-most-of-the-truly-important-evidence medicine.

The evidence-based medicine movement grew out of the work of yet another British epidemiologist, a physician named Archie Cochrane. In 1971, Cochrane published an influential monograph that argued that unsubstantiated claims of effectiveness pervaded many areas of medicine [18]. He argued that more DBRCTs should be conducted, and that their results should be compiled and reviewed systematically. The organizations that do these reviews have been named Cochrane Centers in his honor.

It is good that more medical therapies are being subjected to testing in DBRCTs, and that physicians are demanding more evidence from DBRCTs to guide their own decisions about therapeutics. However, an overzealous insistence on ignoring any data that does not come from a DBRCT could lead the medical profession to ignore the lessons of epidemiology, and thus to dismiss dietary interventions out of hand. Experimentation is only one of the considerations established by Hill. When the other kinds of evidence of association are overwhelming, the purpose of the experiment is simply to provide reassurance that the presumed effect is not due to unidentified confounding variables.

Consider, for example, the effect of diet on heart disease. Several different kinds of studies have shown that people who eat a truly low-fat diet (~10% of calories) and plenty of fiber tend to have a total serum cholesterol of below 150 mg/dL. When total cholesterol is below 150 mg/dL, coronary artery disease simply ceases to exist [19]. Eating even small amounts of animal-based food is associated with a small, but measurable increase in risk of Western disease [20].

In other words, the causal relationship between dietary patterns and coronary artery disease was already well established before Dean Ornish [21] and Caldwell Esselstyn [22] undertook their clinical studies. The value of their studies was not so much in providing evidence that such a dietary change would be effective, but in showing that physicians can persuade their patients to make such changes voluntarily, in the absence of food shortages. These studies also provided interesting data on the speed and magnitude of the change in severe atherosclerotic lesions as a result of dietary therapy. Any complaints that these studies were small or unblinded are simply irrelevant. Because the evidence of the role of diet in causing atherosclerosis is already so overwhelming, assigning a patient to a control group would be major violation of research ethics.

Evidence of the value of a low-fat, plant-based diet for managing obesity, cardiovascular disease, and diabetes has been available in the medical literature for decades. One prominent center of such research was the Rice Diet Program, founded by Walter Kempner of Duke University Medical School [23]. The Nathan Pritikin Research Foundation maintains a bibliography of its ongoing clinical dietary research [24]. John McDougall has shown that patients can achieve dramatic reductions in blood pressure and serum cholesterol levels, along with dramatic improvements in blood sugar control, from 12 days of eating a low-fat, high-fiber, plant-based diet in an inpatient setting [25]. The Physician’s Committee for Responsible Medicine has sponsored important clinical studies of diet through its Washington Center for Clinical Research [26]. Note that all of this research involved a diet that was <10% fat by calorie. In contrast, the American Heart Association recommends a diet that is 25–35% fat by calorie [27].

Denis Burkitt warned us that the rich, fatty Western diet is the standard cause of death and disability in Europe and North America. Yet physicians, especially in the United States, are still busily manning the ambulances at the bottom of the cliff instead of building fences at the top. This pattern is unlikely to change unless medical education and continuing medical education start placing a heavy emphasis on nutrition and dietetics. Unfortunately, that development is unlikely to take place until the medical community overcomes its fixation on a narrow view of evidence-based medicine and embraces Hill’s principles for establishing causality in epidemiology.

Conflict of interest

No grants or other support was given for this article. The author has no conflicts of interest.

References


Table 3

<table>
<thead>
<tr>
<th>Consideration</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timing</td>
<td>A cause must always happen before the result</td>
</tr>
<tr>
<td>Strength of the association</td>
<td>The disease must be more common when the presumed cause is present than when it is not; the stronger the statistical relationship is, the stronger the evidence for a cause-and-effect relationship is</td>
</tr>
<tr>
<td>Dose–response relationship</td>
<td>People who get a bigger dose of the presumed cause should have a higher risk of the disease</td>
</tr>
<tr>
<td>Consistency of the association</td>
<td>The presumed cause should be linked to the disease in many different kinds of studies, and in many different settings</td>
</tr>
<tr>
<td>Plausibility</td>
<td>The cause-and-effect relationship makes sense in terms of what we know about the underlying biology</td>
</tr>
<tr>
<td>Consideration of alternative explanations</td>
<td>The researchers have to rule out other reasonable explanations</td>
</tr>
<tr>
<td>Experiment</td>
<td>The condition can be prevented or otherwise altered by an appropriate experimental regimen</td>
</tr>
<tr>
<td>Specificity of the association</td>
<td>The presumed cause should be associated specifically with a particular disease; of course, the same cause can produce more than one kind of disease</td>
</tr>
<tr>
<td>Coherence</td>
<td>The proposed cause-and-effect relationship should not seriously conflict with other things that we know</td>
</tr>
<tr>
<td>Analogy</td>
<td>Similar causes have been shown to produce similar diseases</td>
</tr>
</tbody>
</table>


